Genetic regulation of the plasma proteome and its link to cardiometabolic disease in Greenlandic Inuit

3

4 Authors

Sara E. Stinson^{1*}, Renzo F. Balboa^{2*}, Mette K. Andersen¹, Frederik F. Stæger², Shixu He², Anne
Cathrine Baun Thuesen¹, Long Lin², Peter Bjerregaard^{3,4}, Christina V.L. Larsen^{3,4}, Niels
Grarup¹, Marit E. Jørgensen^{3,4,5}, Ida Moltke^{2,#}, Anders Albrechtsen^{2,#} and Torben Hansen^{1,#}

8

9 *These authors contributed equally

- 10 [#]Corresponding authors
- 11

12 Affiliations

- ¹Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical
- 14 Sciences, University of Copenhagen, Copenhagen, Denmark
- ²Department of Biology, University of Copenhagen, Copenhagen, Denmark
- ³National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark
- ⁴Greenland Center for Health Research, University of Greenland, Nuuk, Greenland
- 18 ⁵Steno Diabetes Center, Nuuk, Greenland
- 19

20 Corresponding authors

- 21 Addresses: Ole Maaløes Vej 5, DK-2200, Copenhagen N, Denmark (I. Moltke and A.
- 22 Albrechtsen); Blegdamsvej 3B, DK-2200, Copenhagen N, Denmark (T. Hansen).
- 23 Emails: <u>ida@bio.ku.dk</u> (I. Moltke), <u>aalbrechtsen@bio.ku.dk</u> (A. Albrechtsen),
- 24 torben.hansen@sund.ku.dk (T. Hansen)
- 25

26 Keywords

- 27 Proteomics, Genomics, Diverse populations, Greenland Inuit, Cardiovascular disease, Type 2
- 28 diabetes, pQTL analysis

29 Summary

30 Background

Circulating proteins play essential roles in numerous complex diseases, yet our understanding of
the genetic influences on inflammation and cardiovascular-related proteins in non-European
isolated populations remains sparse. Here, we aimed to characterise the genetic architecture of
plasma protein biomarkers in the Greenlandic population.

35

36 Methods

Using combined data from Greenlandic population cohorts (n=3,707 individuals), including
genotypes and plasma proteomics (177 proteins) from Olink Target 96 Inflammation and
Cardiovascular II panels, we performed a protein quantitative trait loci (pQTL) study using a
linear mixed model, accounting for relatedness and population structure.

41

42 Findings

Mapping of 177 plasma proteins in 3,707 adult Greenlandic individuals (mean age 47.9; 54.5%
female) reveal 251 primary pQTLs, 235 additive (92 *cis* and 143 *trans*) and 16 recessive (1 *cis* and 15 *trans*), 48 secondary pQTLs, and 70 novel pQTLs (28%). We demonstrate a higher proportion of variance in protein levels explained in Greenlanders compared to Europeans from the UK Biobank (e.g. IL-27, IgGFcRII-b, IL-16, and Gal-9). We describe changes in expression of inflammation and cardiovascular-related proteins associated with known high impact Arctic-specific variants, including in *CPT1A*, *TBC1D4*, *HNF1A*, *LDLR*, and *PCSK9*.

50

51 Interpretation

52 These findings highlight the importance of genome-wide plasma proteomic analyses in
53 Greenlanders, and diverse populations in general, with implications for biomarker and
54 therapeutic target development.

55

56 Funding

57 Novo Nordisk Foundation, The Independent Research Fund Denmark, and Karen Elise Jensen58 Foundation.

59 **Research in context**

60 Evidence before this study

Recent affinity-based proteomic studies have been performed in large European biobank-scale 61 62 cohorts such as the UK Biobank and deCODE. Several smaller-scale studies have also been performed in isolated European populations, e.g. MANOLIS and Pomak (Hellenic), Orkney 63 64 (Scotland), and Vis (Croatia). Studies in non-European populations are also beginning to emerge, including in the China Kadoorie Biobank. Studies performed in diverse populations can identify 65 66 population-specific variants in genes implicated in regulating the expression of proteins, which 67 may be causally linked to inflammation and cardiovascular disease. In particular, small and 68 historically isolated populations, such as the Greenlandic population, are more likely to harbour 69 common variants with larger effect sizes that may contribute to health and disease.

70

71 Added value of this study

72 This study reports 251 primary protein quantitative trait loci (pQTLs) associated with the 73 abundance of 177 plasma proteins, 28% of which have not been previously reported. We 74 identified 48 additional pQTLs in a secondary conditional analysis. We identified novel pQTLs 75 that were common in Greenland, but rare globally (e.g. ST1A1, DCN). We found common 76 pQTLs which explained a substantial proportion of variance (>30%) in protein abundance (e.g. 77 IL-27, IgGFcRIIb, IL-16, Gal-9) when compared to Europeans. We examined differences in protein abundance in carriers of Arctic-specific variants (e.g. CPT1A, TBC1D4, HNF1A, LDLR, 78 79 PCSK9) which are implicated in lipid metabolism and cardiometabolic disease, revealing 80 underlying biological mechanisms.

81

82 Implications of all the available evidence

Given that both genetics and the environment affect protein levels causally linked to disease, it is
crucial to perform genome-wide association studies in smaller populations of diverse genetic
ancestry to ensure equity in genetic discovery. Investigating the effect of previously identified
Arctic-specific variants on protein expression revealed links to therapeutic targets for metabolic
disease, which may have implications for the health care system in Greenland and beyond,
including access to treatment.

89 Introduction

90 Circulating proteins measured in the blood represent intermediate phenotypes for disease states
91 and are strongly linked to both causative genetic variants and disease outcomes¹. Thus,
92 differences in protein expression make ideal candidates to study, in order to understand the
93 molecular mechanisms of complex disease.

94 Proteomics data has only recently become accessible to large-scale genome-wide association 95 studies (GWAS), largely due to analytical limitations specific to the composition of the plasma 96 proteome². Advances in high-throughput proteomics methods (e.g. Olink, SomaScan, and mass-97 spectrometry approaches) now enable the measurement of plasma levels of hundreds to 98 thousands of proteins concurrently^{3,4}. Unlike mass-spectrometry-based proteomics, the Olink 99 Proximity Extension Assay captures less abundant proteins, allowing for the quantification of 9100 cytokines and chemokines relevant to the pathophysiology of cardiometabolic disease⁵.

101 Identification of genetic variants associated with altered plasma protein levels (protein 102 quantitative trait loci, pQTLs) can enhance our understanding of the role of proteins in health and 103 disease⁶. Discovery of genetic determinants of protein levels help elucidate the causal role of a 104 given protein in disease risk, which may allow for improved risk stratification to enhance early 105 diagnosis and identification of potential drug targets for treatment or prevention of such 106 diseases⁷.

To date, the vast majority of studies have restricted analyses of the genetic architecture of the plasma proteome to European ancestries⁸⁻¹³, this includes large-scale biobanks such as the UK
Biobank Pharma Proteomics Project (UKB-PPP, Olink)¹⁴ and deCODE Genetics (SomaScan).
For example, the discovery analysis in UKB-PPP was limited to European individuals, with replication in a limited number of non-European individuals¹⁴. Although separate efforts have been made to analyse pQTLs in non-EUR, including East Asian^{15,16} and Middle Eastern¹⁷ ancestries, diverse populations are in comparison, highly underrepresented.

114 Two studies have been performed in isolated European populations, including MANOLIS, 115 Pomark, and ORCADES in combination with whole-genome sequencing^{18,19}. Studying isolated 116 populations has the power to enhance the discovery of disease-associated loci due to the 117 enrichment of certain rare variants with larger effects^{20,21}.

118 The Greenlandic population, comprising ~57,000 individuals, mainly has Inuit ancestry, but due to recent admixture it also has some European ancestry²². The population is a small and 119 historically isolated founder population, which has experienced an increase in the prevalence of 120 type 2 diabetes (T2D) over the last 25 years²³. Previous studies of the population have revealed 121 that complex diseases, including T2D, often manifest differently and have Arctic-specific causes, 122 123 when compared to other global populations. How lipid-related and cardiometabolic disease-124 causing variants are associated with differences in protein expression within the Greenlandic 125 population, and its comparison with other populations, have yet to be studied. An investigation 126 into these relationships will allow for a better understanding of the mechanism of disease within 127 this population, and other diverse populations in general.

Here, we examined the genetic architecture of the targeted plasma proteome in 3,707 Greenlanders. The aims of this study were to: (i) perform GWAS of 177 plasma proteins measured by the Olink Target 96 Inflammation and Cardiovascular II panels; (ii) compare the genetic architecture of the targeted proteome between Greenlanders and European populations through comparisons with the UKB-PPP, and (iii) assess the impact of known high impact Arctic-specific variants on circulating protein levels.

134

135 Methods

136 Ethics statement

The study has received ethical approval from the Science Ethics Committee in Greenland (project 505-42, project 505-95, project 2011–13 [ref. no. 2011–056978], project 2017-5582, project 2015–22 [ref. no. 2015-16426], and project 2021-09 [16669546]). The study was conducted in accordance with the Declaration of Helsinki, second revision. All participants gave written informed consent.

142

143 Study populations

144 A total of 3,707 participants with available proteomics, genomics, and phenotype data, were

- 145 included in this study; the participants were pooled from three population-survey cohorts: the
- 146 Greenland Population Study (B99) (n = 15; 1998–2001)²⁴, the Inuit Health in Transition (IHIT)
- 147 cohort $(n = 2,130; 2005-2010)^{25}$, and the B2018 cohort $(n = 1,587; 2017-2019)^{26}$.

148

149 Plasma proteomics

150 Relative levels of 184 plasma proteins were measured in 3,707 participants using the Olink 151 Target 96 Inflammation and Cardiovascular II panels across two batches. Seven proteins were 152 common to both panels, yielding a total of 177 unique proteins that were measured. The Olink 153 batches were bridged and normalised using 16 controls using the OlinkAnalyze R package 154 (https://cran.r-project.org/web/packages/OlinkAnalyze/index.html). Normalised protein expression values (NPX) on a log₂ scale were used for downstream analyses. Protein values 155 156 below the lower limit of detection were included in analyses, while those failing Olink's internal 157 quality control warnings were excluded.

158

159 Genotyping and imputation

All samples were genotyped using the Multi-Ethnic Genotyping Array (MEGA chip, Illumina), composed of ~2M variants across the human genome. This chip was used due to the inclusion of variants selected from Indigenous Americans and East Asians, maximising variant capture in Inuit. Genotypes were jointly called using GenCall within GenomeStudio (Illumina). Duplicate samples, individuals with >0.05 missing genotypes, and variants with >0.01 missing genotypes were excluded from analyses. After quality control, our variant set comprised 1.6M variants used for the present study.

167 The same reference panel described in Senftleber et al.²⁷ was utilised in this study. Briefly, whole 168 genome sequencing data from 447 Greenlanders were genotyped using GATK, and phased using 169 SHAPEIT2²⁸, using available duo/trio information. These data were then combined with 1000 170 Genomes²⁹ data and utilised as a reference for imputing common (MAF >0.5%) variants using 171 IMPUTE2³⁰. The imputed data was used to estimate a genetic relationship matrix (GRM) and 172 admixture proportions for inclusion in genome-wide association analyses, described below.

173 Genome-wide association analyses

174 For association analyses, a linear mixed model (LMM) was used, accounting for relatedness and

- 175 population structure (GEMMA³¹ version 0.98.5). The GRM was estimated from SNPs with <1%
- 176 missingness, a MAF >5%, info-score >0.95. PCAngsd³² was used to calculate per-site inbreeding
- 177 coefficient (site-F) accounting for population structure. Sites with site-F > |0.05| and likelihood-

ratio test P-value $<1x10^{-6}$ were also excluded from the GRM estimation. Association tests 178 179 assuming additive and recessive models were performed using a score test. Effect sizes and 180 standard errors were estimated using a restricted maximum likelihood approach. Normalised 181 protein expression (NPX) values were quantile transformed to a normal distribution using a rank-182 based inverse normal transformation performed separately for each sex. P-values are from 183 analyses of transformed data and effect size estimates are from the same analyses and thus 184 reported in standard deviations as β_{SD} . In all analyses, sex, age, and cohort were included as 185 covariates.

186

187 Definition and refinement of significant loci

Primary pQTLs were first defined by distance-based clumping of \pm 10Mb, reporting one representative SNP-protein association with the lowest P-value. For the proteins that are present in both the Cardiovascular II and Inflammation panels, we took pQTLs with the lowest P-value in either panel to avoid duplication. We reported the total number of identified significant associations using the conventional genome-wide threshold of 5×10^{-8} .

193

Some SNP-protein pairs were genome-wide significant when tested in both additive and recessive models. To avoid double counting and to retain independence, if the same SNP-protein pair was genome-wide significant in both additive and recessive models, we reported the lowest p-value from the two, defined as 'mostly additive' if $P_{add} < P_{rec}$ and 'mostly recessive' if $P_{rec} <$ P_{add} . SNPs within 1Mb significant for the same phenotype were also merged to the SNP with the lowest p-value, even if SNPs were detected with different models.

200

201 To test whether a SNP exhibited a 'truly' additive/recessive mode of inheritance, we tested 202 whether the full model with full flexibility to the mode of inheritance (i.e. the alternative mode of 203 inheritance is added as a covariate in the LMM) was significantly better than when using either 204 an additive or recessive model, respectively. We subsequently defined the following categories 205 for this test using an alpha threshold of 0.05: a) recessive/reject additive - where the full model is 206 significantly better than the additive model, and the full model is not significantly better than the 207 recessive model; b) additive/reject recessive - where the full model is not significantly better 208 than the additive model, and the full model is significantly better than the recessive model; c) co-

209 dominant/reject both - where the full model is significantly better than both the additive and210 recessive models, respectively.

211

212 To perform *cis/trans* classifications, we extracted the start/end information for all proteins by 213 mapping UniProt IDs or gene names to Ensembl BioMart. Using these annotations, pQTLs were 214 subsequently classified into four categories; for each protein, a *cis*-pOTL was defined when a 215 lead SNP resided within 100 Kb upstream or downstream (± 100 Kb) of either the start or end of the gene encoding the associated protein, taking whichever was closer to the SNP; a semi-cis-216 217 pQTL was defined when a SNP resided within ± 100 kb-5Mb of the gene encoding the associated protein; a *semi-trans*-pQTL was defined when a SNP resided within the same chromosome but 218 219 >5Mb away; and a *trans*-pQTL was defined when a SNP was located in a different chromosome 220 with respect to the corresponding protein-coding gene.

221

222 Secondary associations and conditional analyses

To test for secondary signals, we performed conditional analyses where primary SNPs were used as covariates as a factor within both additive and recessive models. SNPs that were genome-wide significant when conditioning with any primary SNP within 10 Mb, were classified as a secondary association.

227 Similar to how we reported primary associations, secondary pQTL were classified as the lowest 228 p-value from either the additive or recessive models, defined as 'mostly additive' if P_{add} < P_{rec} and 229 'mostly recessive' if $P_{rec} < P_{add}$. These secondary associations were then reported with their 230 primary SNP.

231

232 Proportion of variance explained by pQTLs

To ensure a fairer comparison when investigating effect sizes and proportion of variance explained (PVE) by pQTLs, we performed the same GWAS analysis described above using a random subset of 3,707 individuals from the UKB-PPP publication¹⁴. Of the 177 unique proteins assayed within this study, 176 were matched using UniProtIDs (data for VSIG2 was not available in the dataset described by Sun et al.¹⁴).

The following equation was used to estimate PVEs by pQTLs from GWAS summary statisticsfor each protein:



Where β represents the effect size, SE represents the standard error of the effect size, and Nrepresents the number of individuals assayed.

Comparisons were then made between our Greenlandic dataset (n=3,707), the UKB-PPP subset (n=3,707), and the UKB-PPP summary dataset (n=54,219; described in Supplementary Table 10 in Sun et al.¹⁴).

245

246 Identification of novel pQTLs

247 To assess the novelty of the identified pQTLs in this study, we compared our results at genomewide significance level to the results of 34 previously published pQTL studies, including the 248 most recent UKB-PPP publication¹⁴. For all studies, we retained the pOTLs at the reported 249 significance levels. We defined the novelty of locus-protein pairs if no variants residing within \pm 250 251 10Mb of the primary pQTLs in this study had been reported in previous plasma/serum pQTL studies for the corresponding primary protein as in Thareja et al.¹⁷; described in Supplementary 252 Table 4. Comparisons were done at protein level by matching the reported gene name from each 253 254 study. Gene names were mapped based on Uniprot IDs, through Uniprot ID mapping in case of 255 missing values.

In some cases, locus-protein pairs have been previously reported, yet the putative variant within this study could be novel. To identify such variants, we plotted SNP-protein effects from UK Biobank and the Greenlandic study together in Supplementary Figure 1 and for potentially novel pairs in Supplementary Figure 2.

260

261 Analysis of known high-impact cardiometabolic-related variants

262 Summary data describing the associations between known high-impact Arctic-specific variants

263 in CPT1A (rs80356779), TBC1D4 (rs61736969), HNF1A (rs2135845768), LDLR (rs730882082),

and *PCSK9* (rs4609471) on the abundance of 177 Olink proteins measured in this study were
examined. False discovery rate (FDR) was calculated to account for multiple testing.

266

267 Role of funding source

None of the funding agencies had any role in the study design or collection, analysis, orinterpretation of the data.

270

290

271 **Results**

272 Genetic architecture of circulating plasma proteome

273 We analysed 177 proteins measured using the Olink Target Inflammation and Cardiovascular II 274 panels (Supplementary Table 1) in three Greenlandic cohorts, totaling 3,707 participants from 19 275 different localities in Greenland (Supplementary Table 2). To identify pQTLs we used both an 276 additive and a recessive model in a linear mixed model framework, which resulted in low 277 genomic inflation for both the additive (mean $\lambda = 0.985 \pm 0.0246$) and the recessive ($\lambda = 0.989 \pm$ 278 0.0250) model (Supplementary Figure 3). We identified a total of 251 genome-wide significant 279 $(P < 5 \times 10^{-8})$ primary associations between 225 genomic regions and 133 proteins (Figure 1, 280 Supplementary Table 3), where primary associations means that all SNPs associated with the 281 same protein are more than 10Mb apart. Of these primary pQTLs, 235 were classified as mostly 282 additive and 16 as mostly recessive, however, for around one in four we can reject both the 283 additive and the recessive model in favour of the full model (figure 1b). As expected, we found 284 that the majority of primary SNPs were associated with a single protein, yet a large portion of 285 proteins (56.4%) were associated with more than one SNP. In 34 previously published pQTL 286 studies, we found that 181 of our identified locus-protein associations have been previously 287 reported in a peer-reviewed article, and that these are in almost equal proportions in *cis* and *trans* 288 (Figure 1f). Conversely, the vast majority of the remaining 70 (28%) locus-protein pairs were 289 found to be novel (± 10Mb from the nearest variant previously reported to be associated to the

trans or semi-trans (96%; Figure 1f; Figure 1k, Supplementary Table 4). Interestingly, two of the three novel associations reported in *cis* that did not overlap with any of the examined published studies have lead SNPs that are very rare in European populations, yet were common in the Inuit ancestry component of the Greenlanders (chr16:28596376:T:C for ST1A1 - MAF=0.064 in Inuit

same protein in a peer-reviewed article), in which the vast majority of these associations were in

295 and MAF=0.001 in Europeans; chr12:91158410:T:C for DCN - MAF=0.230 in Inuit and 296 MAF<0.001 in Europeans; Supplementary Tables 3 & 4). Of the primary pQTLs, 93 (37%) were local-acting (85 cis, 8 semi-cis; Figure 1k; Methods) and 158 (63%) were distant-acting (14 297 298 semi-trans and 144 trans; Figure 1k; Methods). Of the 177 proteins assayed within this study, 51 299 unique proteins were identified as having both *cis* and *trans* pQTLs (defined as <±5Mb of the gene encoding the associated protein and $>\pm 5$ Mb of the gene encoding the associated protein or 300 301 on a different chromosome, respectively). In addition to the 251 primary associations, 302 conditional analyses further revealed 48 secondary pQTLs, of which, 47 were additive (36 cis, 3 303 semi-cis; 8 trans) and one recessive (in cis) (Supplementary Table 5).

medRxiv preprint doi: https://doi.org/10.1101/2024.07.03.24309577; this version posted July 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



308 Figure 1. Genetic architecture of the targeted plasma proteome in the Greenlandic population. a Manhattan 309 plot of p-values combined for all proteins under additive (red) and recessive (blue) models obtained using GEMMA. 310 A genome-wide significance threshold of 5×10^{-8} is indicated by horizontal blue and red lines. P-values are capped at 1×10^{-50} , as indicated by dotted black lines, **b** Primary pOTLs classified according to inheritance model where 311 312 'additive' and 'recessive' indicate pQTLs that are not rejected in favour of the full model while for 'co-dominant' 313 both the additive and recessive models are rejected. Bar colours indicate the model in which the lowest p-value was 314 reported, where red indicates a lower p-value when using an additive model ('mostly additive') and blue, a lower p-315 value when using a recessive model ('mostly recessive'). c Number of primary pQTLs detected per chromosome. d 316 Number of associated proteins per variant. e Number of primary pQTLs per protein. f Number of known and novel 317 locus-protein associations in cis, semi-cis, semi-trans and trans (defined in k). Known indicates associations within 318 \pm 10Mb of any significant pQTL reported in previous studies (Methods). Novel indicates associations $\geq \pm$ 10Mb of 319 any significant pQTL reported in previous studies (Methods). g Number of proteins with pQTLs in cis, trans or 320 both. Trans pQTLs here are defined as >5Mb from the start/end positions of the primary gene relevant for each 321 Olink protein (a combination of *trans* and *semi-trans* as defined in k, for simplicity). h Dot plot indicating pQTL 322 positions across the genome. Trans pQTLs are defined as >5Mb from the start/end positions of the primary gene 323 relevant for each Olink protein, (a combination of trans and semi-trans as defined in k, for simplicity). Red - cis 324 OTLs; Blue - *trans* pOTLs. i Number of primary pOTLs defined as *cis*, *semi-cis*, *semi-trans* and *trans* (defined in k). 325 j Number of secondary pQTLs defined as cis, semi-cis, semi-trans and trans (defined in k). k Definitions of cis, 326 semi-cis, semi-trans and trans pQTLs. Cis pQTLs are defined as SNP-protein pairs which are within 100kb of the 327 start/end of the gene encoding the associated protein. Semi-cis pQTLs are defined as SNP-protein pairs which are 328 between 100-kb-5Mb of the start/end of the gene encoding the associated protein. Semi-trans pQTLs are defined as 329 SNP-protein pairs which are >5Mb of the start/end of the encoding gene, but on the same chromosome. Trans 330 pQTLs are defined as SNP-protein pairs which are on different chromosomes from the gene encoding the associated 331 protein.

332

333 Common, high-impact pQTLs in Greenlanders

We next explored PVE for pQTLs detected in Greenlandic individuals and performed 334 comparisons with Olink data from the UK Biobank¹⁴. The UK Biobank individuals tended to 335 have a larger proportion of significant pQTLs with a lower PVE, and exhibited a lower number 336 337 of high-impact pQTLs compared to the Greenlandic individuals (Figure 2a-b, Supplementary Table 6). In the Greenlandic individuals, several proteins, including IL-27, IgGFcRII-b, MCP-2 338 339 and IL-16 and Gal-9 exhibited PVEs >30% (Figure 2a). PQTLs related to the same proteins in 340 UK Biobank exhibited PVEs <20% and were generally less common in allele frequency when compared to Greenlanders (Figure 2bi-iii). Two of these variants, rs1801274 associated with 341 IgGFcRII-b, rs142653327 associated with Gal-9, are missense variants. Specifically, the 342

association of IgGFcII-b rs1801274 G-allele has been shown to confer susceptibility to
autoimmune diseases, including Kawasaki disease and ulcerative colitis³³. Furthermore,
rs142653327 is a novel pQTL variant for Gal-9, which is not present in Europe (Figure 2c).
However, a secondary association for Gal-9 found in Greenland was also significant within UK
Biobank (rs112305547; Figure 2c). Overall, these results suggest that Greenlanders exhibit more
common and high-impact variants when compared to UK Biobank individuals, and that some of
these variants may carry a functional impact.



352

353 Figure 2. Proportion of variance explained by pQTLs in Greenlanders vs Europeans from UK Biobank. a 354 Proportion of variance explained (PVE) for Greenlanders (GRL; green; n=3,707) and the UK Biobank cohort¹⁴ 355 (UKB; blue; n=3.707) for 176 proteins common between both studies, ordered by highest PVEs in Greenlanders 356 (top) and highest PVEs in UKB (bottom). Dashed lines indicate the equivalent PVE for each protein as reported in 357 Greenlanders (top) and UKB (bottom), respectively. b PVE vs minor allele frequency (MAF) for genome-wide 358 significant pQTLs detected in (i) Greenlandic individuals using GEMMA (n=3,707); (ii) a random subset of UKB 359 individuals using GEMMA (n=3,707); and (iii) using summary statistics from Sun et al. (2024) (n=54,219). pQTLs 360 with PVE >30% for either Greenlandic individuals, UKB individuals or both in (i) and (ii) are highlighted in green, 361 blue and turquoise, respectively. PVE >30% for Greenlandic individuals, and PVE >15% for UKB individuals or 362 meeting both criteria in (iii) are highlighted in green, blue and turquoise, respectively. c Comparisons of $-\log_{10} P$ 363 values for variant-protein associations described by the Greenlanders dataset (n=3,707), and a subset of individuals 364 from the UKB-PPP (n=3,707). Variant-protein associations tested using an additive model between Gal-9 and SNPs 365 within 5Mb of rs142653327 are plotted. Red lines indicate $-\log_{10} P$ values of 0 for both datasets. Points at -1 indicate 366 associations that were unable to be overlapped with the orthogonal dataset. Green circle - indicates the lead QTL in 367 the Greenland cohort (rs142653327); Blue circle - indicates the lead secondary association reported in the Greenland 368 cohort (rs112305547).

369

370 Associations with known high-impact Arctic-specific variants

371 Previous studies have identified causal, high-impact variants related to population-specific 372 effects for lipid metabolism, T2D, and CVD within Greenlanders, including $CPT1A^{34}$, 373 $TBC1D4^{35}$, $HNF1A^{36}$, $LDLR^{37}$, and $PCSK9^{27}$. As such, we investigated the protein expression for 374 these known variants to gain a better understanding of potential mechanisms leading to these trait 375 differences (Figure 3).

376

377 A known variant in *CPT1A* (rs80356779)³⁴, previously found to modulate fatty acid composition, 378 with large effect sizes on weight and height, herein was associated with lower plasma levels of 379 55 proteins at a significance level of FDR<0.05, including eight proteins significant at 380 FDR<0.001. Stem cell factor, also termed kit ligand (SCF/KITLG) and follistatin (FS) 381 represented the most significant proteins associated with this variant.

382

383 The known high-impact variant in *TBC1D4* $(rs61736969)^{35}$, which causes insulin resistance in 384 the skeletal muscle and explains a significant proportion of the variance in diabetes cases in

Greenland, was associated with lower levels of nine plasma proteins after a 5% FDR correction
(i.e. IL-6, IL-18, CCL-19, CCL-28, CD40L, ITGB1BP2, PD-L1, STAMBP and SIRT2).

387

A variant in the maturity onset diabetes of the young (MODY) gene, *HNF1A* (rs2135845768)³⁶, which explains up to 2.5% of variance in diabetes in Greenland (together with *TBC1D4* explains up to 18% of diabetes cases), was associated with lower plasma levels of two proteins (angiotensin converting enzyme 2 [ACE2] and chymotrypsin-C [CTRC]) and higher levels of two proteins (oncostatin-M [OSM] and protransforming growth factor alpha [TGF-alpha]), after a 5% FDR correction.

394

A known variant in *LDLR* (rs730882082)³⁷ which has a large impact on familial hypercholesterolemia (FH) in Greenland, was associated with lower plasma levels of one protein (fibroblast growth factor 21 [FGF-21]), and higher levels of two proteins (glial cell line-derived neurotrophic factor [GDNF] and interleukin-4 [IL-4]), after a 5% FDR correction.

399

400 The *PCSK9* loss-of-function variant (p.Arg46Leu; rs11591147) originally identified in European

401 GWAS has led to PCSK9-inhibitors as a treatment for dyslipidemia³⁸. We examined whether any

402 proteins were associated with the recently identified *PCSK9* $(rs4609471)^{27}$ variant in Greenland,

403 but found no significant differences, after correction for multiple testing using FDR.





Figure 3. Known high-impact cardiometabolic-related Greenlandic variants. a Significant associations between 406 407 known high-impact cardiometabolic-related Greenlandic variants - CPTIA (rs80356779), HNFIA (rs2135845768), 408 TBC1D4 (rs61736969), LDLR (rs730882082) and PCSK9 (rs4609471) - and inflammatory and cardiovascular-409 related plasma proteins (FDR<0.05). Bubble sizes describe significance levels after multiple testing; small bubbles 410 indicate pQTLs with FDR<0.05 and large bubbles FDR<0.01. Red - higher abundance; blue - lower abundance. b 411 Forest plots for known high-impact variants within the same five genes and the top 20 proteins with the lowest FDR. 412 The centre estimate and error bars on the x-axis describe the effect size (β) ± 95% CI.

413 **Discussion**

414 Here, we present a pQTL study in an isolated non-European population with 177 circulating 415 inflammation- and cardiovascular-related proteins, measured using the Olink Proximity 416 Extension Assay in 3,707 Greenlanders. We identified 251 genome-wide significant primary 417 locus-protein pairs (93 cis, 158 trans), involving 225 different loci for 133 unique proteins. The 418 251 primary locus-protein pairs included many of the same locus-protein pairs found in prior 419 studies performed in Europeans, with 181 (~72.1%) reported previously in 34 peer-reviewed 420 studies, but also revealed 70 locus-protein pair associations (3 cis, 6 semi-trans, 61 trans) that 421 have not been reported previously. We identify 16 pQTLs which are purely recessive, 15 out of 422 16 are in semi-trans/trans (e.g. PRSS27, FABP2 and TF). This highlights the importance of 423 conducting analyses in diverse populations, including alternative modes of inheritance.

424

425 Cross-ancestry differences have been highlighted by a previous mass-spectrometry based 426 proteomics study conducted in a population of 2,958 Han Chinese participants, wherein proteins 427 which are positively associated with BMI in European populations, showed opposite direction of effects in East Asians.¹⁵ An additional study found that up to 89% of pQTLs identified in 428 429 European studies can be replicated in an Arab population of 2,935 individuals, when using the SOMAscan platform.¹⁷ So far, the pQTL studies performed in isolated populations are of 430 431 European ancestry. An earlier study used a unique approach of whole-genome sequencing and three Olink panels (CVDI, CVDII, metabolism) across three isolated European cohorts 432 (MANOLIS, Pomak, and ORCADES), identifying 5 rare variant pQTLs.¹⁸ 433

434

To examine whether high-impact pQTLs were more common in the Greenlandic population, we performed an additional GWAS for a subset of UK Biobank individuals, matched by the sample size of our analysis for Greenlanders (n=3,707 in both populations) and using both additive and recessive models. The three pQTLs with the highest PVE in Greenlanders (IL-27, IgGFcRII-b, MCP-2) explained 44.3%, 43.7%, and 43.2%, compared to the top three pQTLs in the samplesize matched UK Biobank (CD6, MCP-2, IL-18R1) GWAS, which explained 33.9%, 30.0%, and 26.9%.

443 Certain genetic variants have undergone selection as an adaptation to the extreme conditions of 444 the Arctic and the intake of specialised diets rich in proteins and polyunsaturated fatty acids 445 (PUFAs). An example of this is the Arctic-specific variant in CPT1A (rs80356779), which is a 446 known modulator of fatty acid composition (including decreased levels of circulating omega-6 447 and increased omega-3 PUFAs), which may affect the regulation of growth hormones, with large effects on height and weight³⁴. Herein, we demonstrated that this variant has pleiotropic effects 448 449 on plasma protein levels, with a general pattern of reduced inflammatory and cardiovascular-450 related protein biomarkers, which may be a result of the reduction in circulating PUFAs, 451 primarily omega-6. CPT1A carriers exhibited significantly lower plasma levels of SCF, a protein 452 that has been shown to play a central role in inflammation (cell survival, proliferation, and hematopoiesis) and is a suggested therapeutic target for inflammatory diseases³⁹. *CPT1A* carriers 453 454 also had significantly lower plasma levels of FS, a hepatokine which is elevated in patients with T2D and is associated with adipose tissue insulin resistance 40 . 455

456

The common loss-of-function variant in $TBC1D4^{35}$ (rs61736969) responsible for muscle insulin 457 resistance and explains up to 15.5% of variance in diabetes in Greenland, and in the present 458 459 study was associated with lower expression of nine plasma proteins, most of which are 460 interleukins (IL-6, IL-18), chemokines (CCL-19, CCL-28), other immune mediators (CD40L, 461 PD-L1), integrins (ITGB1BP2), metalloproteases (STAMBP), and transferases (SIRT2). IL-6 is 462 elevated with obesity, but on the other hand is also secreted as a myokine from muscles during 463 exercise, exerting anti-inflammatory and anti-diabetogenic effects. Physical activity has been shown to reduce postprandial hyperglycemia in *TBC1D4* carriers⁴¹, and IL-6 levels may be 464 increased as a result of exercise. Moreover, lower expression of ITGB1BP2 (integrin beta-1-465 466 binding protein 2) was also observed in TBC1D4 carriers, a protein that plays an essential role in the maturation and organisation of muscle cells⁴², which could be driven by the impaired insulin 467 468 resistance in skeletal muscle. It remains unclear whether TBC1D4 carriers are at an increased risk of cardiovascular disease⁴³. In the present study, we see elevations in several cardiovascular-469 disease related biomarkers, including ITGB1BP2⁴², STAMBP (linked to congenital 470 malformations of the heart)⁴⁴ and SIRT2 (functions in inhibiting pathological cardiac 471 hypertrophy)⁴⁵. 472

The known Inuit-specific variant in the MODY gene *HNF1A*³⁶ (rs2135845768), explaining up to 2.5% of variance in diabetes in Greenland, was associated with altered expression of four (ACE2, CTRC, OSM, TGF-alpha) proteins in the present study. Plasma abundance of ACE2 was significantly lower in *HNF1A* carriers. *HNF1A* is known to induce ACE2 expression in the pancreatic islet cells. ACE2 plays an important role in maintaining glycemia and β-cell function, and has been suggested as a potential therapeutic target for treatment of diabetes⁴⁶.

480

A known Arctic-specific variant in LDLR³⁷ (rs730882082) which poses a high risk of FH in 481 482 nearly 30% of Greenlanders, associated with altered expression of three plasma proteins (FGF-483 21, GDNF, and IL-4) in the present study. Specifically, FGF-21 levels were lower in carriers of 484 the LDLR variant, a protein responsible for fatty acid oxidation and regulation of systemic 485 glucose homeostasis and insulin sensitivity. FGF-21 analogs are being developed for their beneficial effects on modulate lipid and lipoprotein levels, and therefore could potentially serve 486 as treatment for patients with FH⁴⁷. Clinical trials for FGF-21 analogs are also ongoing for 487 488 metabolic-dysfunction-associated steatotic liver disease.

489

490 Limitations

491 Our study has several limitations. Firstly, our pQTL analysis is restricted to the 177 proteins 492 measured by two Olink panels. An untargeted approach would allow for identification of more 493 and potentially novel pQTLs, yet targeted approaches allow for the study of biologically relevant 494 protein biomarkers. Inclusion of orthogonal methods such as mass spectrometry-based 495 proteomics, would resolve the possibility of epitope effects, yet this kind of validation is difficult 496 to perform at scale. Tissue- and cell-type specific pQTL studies will be valuable in future studies 497 to understand differences in genetic signals across tissues. We did not examine ratios between 498 protein levels which may identify novel associations, when multiple proteins are associated with the same variant⁴⁸. Furthermore, the raw abundance of proteins does not take into consideration 499 500 protein-protein interactions, mapping the interactome can lead to additional biological insights⁴⁹.

501 Strengths

502 Identification of pQTLs aid in the understanding of mechanisms of complex disease and can 503 identify promising targets for pharmacological interventions. The majority of all pQTL studies 504 performed to date have been conducted in European populations, limiting the generalizability of

505 findings across populations. Although an attempt was made to identify pOTLs in non-European 506 ancestry in the UKB-PPP (953 with South Asian and 1,513 with African ancestry), the sample size is smaller than the present study⁵⁰. Here, we explore pQTLs in a historically isolated 507 508 Greenlandic population, identify associations related to alternative modes of inheritance, and 509 highlight the need to study diverse populations, through comparisons to large datasets generated 510 in the UK Biobank, primarily of European ancestry. The challenge in genetic research in 511 indigenous populations is that it raises complex psychological, ethical, social, and political 512 issues. These issues have been raised in a series of user surveys on the use of genetics in 513 metabolic research. Generally, the communities fully support the research with a specific request 514 to investigate the significance of traditional and modern Inuit lifestyle, in order to understand 515 how advising individuals regarding diet and lifestyle, can be linked in a culturally appropriate 516 way, to better inform health effects of genetic profiles.

517

518 **Conclusions**

The pQTLs identified and analysed in this study provide a resource to unravel the genetic architecture of the targeted plasma proteome in the Greenlandic population. There was a larger proportional variance explained in Greenlanders when compared to European ancestries, which has relevant implications for disease outcomes. Variants with large population impact on lipid metabolism (*CPT1A*) and risk of cardiometabolic disease in Greenland (*TBC1D4*, *HNF1A*, and *LDLR*), show distinct patterns with inflammatory cytokines and cardiovascular disease biomarkers, pointing towards potential therapeutic targets.

- 526
- 527

528 **Contributors**

- Conceptualization: SES, RFB, MKA, NG, MEJ, IM, AA, TH
- Data curation: SES, MKA, ACBT, NG, MEJ, IM, AA, TH
- Formal analysis: SES, RFB, FFS, SH, LL
- Funding acquisition: PB, CVLL, NG, MEJ, IM, AA, TH
- Investigation: SES, RFB, FFS, PB, CVLL, NG, MEJ, IM, AA, TH
- Methodology: SES, RFB, FFS, NG, MEJ, IM, AA, TH
- Project administration: SES, RFB, MKA, PB, CVLL, NG, MEJ, IM, AA, TH
- Resources: PB, CVLL, NG, MEJ, IM, AA, TH
- 537 Software: AA
- Supervision: NG, IM, AA, TH
- User surveys: MEJ
- Visualisation: SES, RFB, FFS, IM, AA, TH
- Writing original draft: SES, RFB, IM, AA, TH
- Writing review & editing: MKA, FFS, SH, ACBT, LL, PB, CVLL, NG, MEJ
- 543

544 Data sharing statement

545 Summary data from the study may be available by reasonable request to the authors.

546

547 **Declaration of interests**

548 The population surveys of Greenland were funded by the Department of Health, Greenland, The 549 Novo Nordisk Foundation (NNF17OC0028136 & NNF17SH0027192), The Independent 550 Research Fund Denmark, and Karen Elise Jensen Foundation. The Novo Nordisk Foundation 551 Center for Basic Metabolic Research is an independent research centre at the University of 552 Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation 553 (NNF18CC0034900). SES received funding from The Novo Nordisk Foundation, Copenhagen 554 Bioscience PhD Program (grant number: NNF18CC0033668). RFB and IM are supported by a 555 Villum Young Investigator grant (VIL19114), awarded to IM. RFB, SH, LL and AA are funded 556 by the Novo Nordisk Foundation (NNF20OC0061343). AA is supported by the Independent 557 Research Fund Denmark (8021-00360B). None of the funding agencies had any role in study

design or collection, analysis, or interpretation of data. NG is currently employed at NovoNordisk. All other authors have no further conflicts of interest to declare.

560

561 Acknowledgements

We would like to acknowledge all the participants and the staff of the Greenland PopulationHealth Surveys (Befolkningsundersøgelsen i Grønland). We would also like to thank Annemette

564 Forman and Tina Hvidtfeldt Lorentzen from the Novo Nordisk Foundation Center for Basic

- 565 Metabolic Research, University of Copenhagen for their technical support.
- 566
- 567 Appendix A. Supplementary Data

568

569 Appendix B. Supplementary Figures

571 **References**

- Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function.
 Nature 2016; **537**: 347–55.
- 574 2 Deutsch EW, Omenn GS, Sun Z, *et al.* Advances and Utility of the Human Plasma
 575 Proteome. *J Proteome Res* 2021; 20: 5241–63.
- 576 3 Katz DH, Robbins JM, Deng S, *et al.* Proteomic profiling platforms head to head:
 577 Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods.
 578 *Sci Adv* 2022; 8: eabm5164.
- Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. The emerging role of mass
 spectrometry-based proteomics in drug discovery. *Nat Rev Drug Discov* 2022; 21: 637–54.
- 581 5 Smith JG, Gerszten RE. Emerging Affinity-Based Proteomic Technologies for Large-Scale
 582 Plasma Profiling in Cardiovascular Disease. *Circulation* 2017; **135**: 1651–64.
- 583 6 Suhre K, McCarthy MI, Schwenk JM. Genetics meets proteomics: perspectives for large
 584 population-based studies. *Nat Rev Genet* 2020; 22: 19–37.
- Aguet F, Alasoo K, Li YI, *et al.* Molecular quantitative trait loci. *Nature Reviews Methods Primers* 2023; 3: 1–22.
- 587 8 Sun BB, Maranville JC, Peters JE, *et al.* Genomic atlas of the human plasma proteome.
 588 *Nature* 2018; **558**: 73–9.
- Pietzner M, Wheeler E, Carrasco-Zanini J, *et al.* Mapping the proteo-genomic convergence
 of human diseases. *Science* 2021; **374**: eabj1541.
- Folkersen L, Gustafsson S, Wang Q, *et al.* Genomic and drug target evaluation of 90
 cardiovascular proteins in 30,931 individuals. *Nature Metabolism* 2020; 2: 1135–48.
- 593 11 Emilsson V, Ilkov M, Lamb JR, *et al.* Co-regulatory networks of human serum proteins link
 594 genetics to disease. *Science* 2018; **361**: 769–73.
- Enroth S, Johansson A, Enroth SB, Gyllensten U. Strong effects of genetic and lifestyle
 factors on biomarker variation and use of personalized cutoffs. *Nat Commun* 2014; 5: 4684.
- 597 13 Suhre K, Arnold M, Bhagwat AM, *et al.* Connecting genetic risk to disease end points
 598 through the human blood plasma proteome. *Nat Commun* 2017; 8: 14357.
- Sun BB, Chiou J, Traylor M, *et al.* Plasma proteomic associations with genetics and health
 in the UK Biobank. *Nature* 2023; 622: 329–38.

Ku F, Yu EY-W, Cai X, *et al.* Genome-wide genotype-serum proteome mapping provides
 insights into the cross-ancestry differences in cardiometabolic disease susceptibility. *Nat Commun* 2023; 14: 1–12.

Said S, Pozarickij A, Lin K, *et al.* Ancestry diversity in the genetic determinants of the
human plasma proteome and associated new drug targets. medRxiv. 2023; :
2023.11.13.23298365.

- Thareja G, Belkadi A, Arnold M, *et al.* Differences and commonalities in the genetic
 architecture of protein quantitative trait loci in European and Arab populations. *Hum Mol Genet* 2023; **32**: 907–16.
- 610 18 Gilly A, Klaric L, Park Y-C, *et al.* Gene-based whole genome sequencing meta-analysis of
 611 250 circulating proteins in three isolated European populations. *Mol Metab* 2022; 61:
 612 101509.
- Png G, Barysenka A, Repetto L, *et al.* Mapping the serum proteome to neurological diseases using whole genome sequencing. *Nat Commun* 2021; 12: 1–12.
- Wojcik GL, Graff M, Nishimura KK, *et al.* Genetic analyses of diverse populations
 improves discovery for complex traits. *Nature* 2019; **570**: 514–8.
- Easteal S, Arkell RM, Balboa RF, *et al.* Equitable Expanded Carrier Screening Needs
 Indigenous Clinical and Population Genomic Data. *Am J Hum Genet* 2020; **107**: 175–82.
- Moltke I, Fumagalli M, Korneliussen TS, *et al.* Uncovering the genetic history of the
 present-day Greenlandic population. *Am J Hum Genet* 2015; **96**: 54–69.
- Jørgensen ME, Bjeregaard P, Borch-Johnsen K. Diabetes and impaired glucose tolerance
 among the inuit population of Greenland. *Diabetes Care* 2002; 25: 1766–71.
- Bjerregaard P, Curtis T, Borch-Johnsen K, *et al.* Inuit health in Greenland: a population
 survey of life style and disease in Greenland and among Inuit living in Denmark. *Int J Circumpolar Health* 2003; 62 Suppl 1: 3–79.
- Jørgensen ME, Borch-Johnsen K, Stolk R, Bjerregaard P. Fat distribution and glucose
 intolerance among Greenland Inuit. *Diabetes Care* 2013; 36: 2988–94.
- Bjerregaard P, Larsen CVL, Olesen I, *et al.* The Greenland population health survey 2018 –
 methods of a prospective study of risk factors for lifestyle related diseases and social
 determinants of health amongst Inuit. *Int J Circumpolar Health* 2022; published online June
 16. DOI:10.1080/22423982.2022.2090067.
- 632 27 Senftleber NK, Andersen MK, Jørsboe E, *et al.* GWAS of lipids in Greenlanders finds
 633 association signals shared with Europeans and reveals an independent PCSK9 association
 634 signal. *Eur J Hum Genet* 2023; published online Oct 30. DOI:10.1038/s41431-023-01485-8.
- Delaneau O, Zagury J-F, Marchini J. Improved whole-chromosome phasing for disease and
 population genetic studies. *Nat Methods* 2013; 10: 5–6.
- 637 29 A global reference for human genetic variation. *Nature* 2015; **526**: 68–74.

- Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method
 for the next generation of genome-wide association studies. *PLoS Genet* 2009; 5: e1000529.
- Stephens M. Genome-wide efficient mixed-model analysis for association studies.
 Nat Genet 2012; 44: 821–4.
- 642 32 Meisner J, Albrechtsen A. Inferring Population Structure and Admixture Proportions in
 643 Low-Depth NGS Data. *Genetics* 2018; **210**: 719–31.
- 33 Zhang C 'e, Wang W, Zhang H 'e, Wei L, Guo S. Association of FCGR2A rs1801274
 polymorphism with susceptibility to autoimmune diseases: A meta-analysis. *Oncotarget*2016; 7: 39436–43.
- Fumagalli M, Moltke I, Grarup N, *et al.* Greenlandic Inuit show genetic signatures of diet
 and climate adaptation. *Science* 2015; **349**: 1343–7.
- Moltke I, Grarup N, Jørgensen ME, *et al.* A common Greenlandic TBC1D4 variant confers
 muscle insulin resistance and type 2 diabetes. *Nature* 2014; **512**: 190–3.
- 651 36 Thuesen ACB, Stæger FF, Kaci A, *et al.* A novel splice-affecting HNF1A variant with large
 652 population impact on diabetes in Greenland. *Lancet Reg Health Eur* 2023; 24: 100529.
- 37 Jørsboe E, Andersen MK, Skotte L, *et al.* An LDLR missense variant poses high risk of
 amilial hypercholesterolemia in 30% of Greenlanders and offers potential of early
 cardiovascular disease intervention. *HGG Adv* 2022; **3**: 100118.
- Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials.
 Circ Res 2018; 122: 1420–38.
- Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. *Eur J Pharmacol* 2006; **533**: 327–40.
- Wu C, Borné Y, Gao R, *et al.* Elevated circulating follistatin associates with an increased
 risk of type 2 diabetes. *Nat Commun* 2021; **12**: 1–10.
- 662 41 Schnurr TM, Jørsboe E, Chadt A, *et al.* Physical activity attenuates postprandial
 663 hyperglycaemia in homozygous TBC1D4 loss-of-function mutation carriers. *Diabetologia*664 2021; 64: 1795–804.
- Brancaccio M, Fratta L, Notte A, *et al.* Melusin, a muscle-specific integrin beta1-interacting
 protein, is required to prevent cardiac failure in response to chronic pressure overload. *Nat Med* 2003; 9: 68–75.
- 43 Jørgensen ME, Tvermosegaard M, Rønn PF, *et al.* Do Greenlandic Carriers of the TBC1D4
 p.Arg684Ter Variant Have Increased Risk of Cardiovascular Disease? *Diabetes* 2018; 67:
 439 P.
- 671 44 Spielmann N, Miller G, Oprea TI, et al. Extensive identification of genes involved in

- 672 congenital and structural heart disorders and cardiomyopathy. *Nature Cardiovascular*673 *Research* 2022; 1: 157–73.
- Wu B, You S, Qian H, *et al.* The role of SIRT2 in vascular-related and heart-related diseases: A review. *J Cell Mol Med* 2021; 25: 6470–8.
- 46 Pedersen KB, Chhabra KH, Nguyen VK, Xia H, Lazartigues E. The transcription factor
 677 HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets
 678 from evolutionarily conserved promoter motifs. *Biochim Biophys Acta* 2013; 1829: 1225–
 679 35.
- Besseling J, Ong KL, Huijgen R, *et al.* The impact of LDLR function on fibroblast growth
 factor 21 levels. *Atherosclerosis* 2015; 241: 322–5.
- 48 Suhre K. Genetic associations with ratios between protein levels detect new pQTLs and
 reveal protein-protein interactions. bioRxiv. 2023; published online July 20.
 DOI:10.1101/2023.07.19.549734.
- 49 Joshi A, Rienks M, Theofilatos K, Mayr M. Systems biology in cardiovascular disease: a
 multiomics approach. *Nat Rev Cardiol* 2021; 18: 313–30.
- 50 Eldjarn GH, Ferkingstad E, Lund SH, *et al.* Large-scale plasma proteomics comparisons
 through genetics and disease associations. *Nature* 2023; **622**: 348–58.